Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To learn if adding lurbinectedin to the combination of paclitaxel and bevacizumab can help to control advanced cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony histologicznie rak jajnika, jajnowodu lub otrzewnej
- •Choroba oporna na platynę (nawrót w ciągu 1-6 miesięcy po leczeniu) lub refrakteryjna (progresja podczas lub do 4 tygodni po platynie)
- •Poprzednie leczenie systemowe dopuszczalne, w tym wcześniejsze terapie anty-VEGF
- •Dobry stan ogólny (ECOG 0-1)
- •Prawidłowe wyniki badań krwi (hemoglobina, białe krwinki, płytki)
- •Prawidłowe wyniki testów wątroby i nerek
- •Kobieta po menopauzie lub ujemny test ciąży
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
M D Anderson Cancer Center
Houston, United States
Trial contact
Shannon Westin, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.